LLY

F-18 AMYVID B+4

There is no specific bill filed. Engagement relates to issues on healthcare and trade. There is no specific bill filed. Engagement relates to issues on healthcare and trade.

Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program. Issues related to drug compounding.

Monitored Issues and advised clients on matters related to Pharmaceutical supply chain security and resiliency.

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program. Issues related to treatments for Alzheimers therapeutics.

General Healthcare Issues pertaining to Eli Lilly and Company, including but not limited to drug pricing, importation and innovation policies.

Alzheimer's Disease. Anti Obesity Medication. Medicare/Medicaid Coverage and Reimbursement. PDUFA. 340B Program.

IRA, non-interference, drug shortages, prescription drug access and affordability, transparency, insulin policy, drug pricing in federal programs Medicare & Medicaid payment and coverage issues, Medicare Part D, Medicare Part B, drug pricing in federal programs federal budget issues

International and domestic tax issues. Implementation of PL 119-21. 340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices. Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment. Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights. Issues related to pharmaceutical manufacturing and development. Drug importation, prescription drug safety, value and access.

Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs. Issues related to intellectual property protection, enforcement and market access issues within trade negotiations; supply chain management; issues related to China trade; Issues related to global health; and issues related to tariffs.

Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain